9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative)
Key Takeaways
- Metastatic NSCLC management requires upfront broad-panel Next-Generation Sequencing (NGS) and PD-L1 immunohistochemistry to delineate actionable oncogenic driver alterations from driver-negative, biomarker-stratified disease prior to initiating first-line therapy.
- For driver-negative non-squamous metastatic NSCLC with PD-L1 <50%, the standard frontline regimen is pembrolizumab plus carboplatin (or cisplatin) plus pemetrexed (KEYNOTE-189) with mandatory folic acid, vitamin B12, and dexamethasone premedication; squamous disease is treated with pembrolizumab plus carboplatin plus paclitaxel/nab-paclitaxel (KEYNOTE-407).
- Osimertinib monotherapy (FLAURA) or osimertinib plus platinum/pemetrexed (FLAURA2) represents the frontline standard of care for classical EGFR-sensitizing mutations (Ex19del, L858R), demonstrating superior intracranial penetration and progression-free survival over 1st/2nd-generation TKIs.
- Next-generation ALK/ROS1 inhibitors (alectinib, brigatinib, lorlatinib, repotrectinib) provide profound systemic and intracranial control; lorlatinib uniquely overcomes the G1202R solvent-front resistance mutation but requires clinical management of hyperlipidemia and neurocognitive toxicities.
- Rare actionable driver alterations in NSCLC—including KRAS G12C (sotorasib, adagrasib), MET exon 14 skipping (capmatinib, tepotinib), RET fusions (selpercatinib, pralsetinib), BRAF V600E (dabrafenib + trametinib), and HER2 mutations (trastuzumab deruxtecan)—mandate target-specific oral kinase inhibitors or antibody-drug conjugates.
Last updated: August 2026
9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative)
Metastatic (Stage IV) Non-Small Cell Lung Cancer represents the archetype of modern precision oncology. Historically treated with empiric, palliative platinum-doublet cytotoxic regimens yielding a median overall survival (OS) of 8–10 months, Stage IV NSCLC is now stratified into distinct molecular and immunologic subsets. Management hinges upon comprehensive Next-Generation Sequencing (NGS) and PD-L1 immunohistochemistry (IHC) to match each patient with target-specific tyrosine kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), or immune checkpoint inhibitor (ICI) combinations.
+-----------------------------------------------------------------------------+
| STAGE IV NSCLC INITIAL BIOMARKER TRIAGE |
| |
| [METASTATIC NSCLC CONFIRMED (HISTOLOGY: SQUAMOUS VS NON-SQUAMOUS)] |
| | |
| v |
| [MANDATORY COMPREHENSIVE BIOMARKER PROFILING (TISSUE NGS + ctDNA + IHC)] |
| - Actionable Driver Oncogenes: EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, |
| MET ex14 skip, RET, NTRK1/2/3, ERBB2 (HER2) |
| - Immunologic Biomarkers: PD-L1 Tumor Proportion Score (TPS: 22C3/SP263) |
| | |
| +-------------------------+-------------------------+ |
| | | |
| v v |
| [ACTIONABLE DRIVER IDENTIFIED] [DRIVER NEGATIVE / WT] |
| Initiate First-Line Targeted TKI Stratify by PD-L1 TPS & |
| (e.g., Osimertinib, Alectinib, Histology (Squamous vs |
| Selpercatinib, Capmatinib) Non-Squamous) |
| *AVOID FRONT-LINE IMMUNOTHERAPY* *CHEMOIMMUNOTHERAPY / ICI* |
+-----------------------------------------------------------------------------+
[!IMPORTANT] Critical Practice Standard: Biomarker Turnaround & Immunotherapy Gating Immune checkpoint inhibitors (single-agent pembrolizumab, atezolizumab, or chemoimmunotherapy) demonstrate exceedingly poor response rates in patients with classic driver oncogenes (EGFR mutations, ALK fusions, ROS1 fusions), despite high PD-L1 expression. Furthermore, administering PD-1/PD-L1 inhibitors immediately prior to starting EGFR or ALK TKIs significantly increases the risk of severe, life-threatening immune-mediated hepatotoxicity and interstitial lung disease (ILD). Clinicians must wait for NGS results before committing to frontline immunotherapy.
1. Driver-Negative Metastatic NSCLC: Biomarker-Directed Frontline Algorithms
For patients without actionable driver alterations, treatment selection is governed by PD-L1 Tumor Proportion Score (TPS) and histologic subtype (Non-Squamous vs. Squamous).
+-----------------------------------------------------------------------------+
| DRIVER-NEGATIVE FRONTLINE TREATMENT ALGORITHM |
| |
| [PD-L1 TUMOR PROPORTION SCORE (TPS)] |
| | |
| +---------------------------+---------------------------+ |
| | | |
| v v |
| [PD-L1 HIGH: TPS >= 50%] [PD-L1 < 50% OR |
| - Single-Agent Immunotherapy: HIGH TUMOR BURDEN] |
| * Pembrolizumab 200 mg Q3W (KEYNOTE-024) | |
| * Atezolizumab 1200 mg Q3W (IMpower110) | |
| * Cemiplimab 350 mg Q3W (EMPOWER-Lung 1) | |
| - (Chemoimmunotherapy preferred if high | |
| symptom burden or visceral crisis) | |
| | |
| +-------------------------------------------------------+ |
| | |
| v |
| [HISTOLOGY STRATIFICATION] |
| | |
| +---------------------------+ |
| | | |
| v v |
| [NON-SQUAMOUS HISTOLOGY] [SQUAMOUS HISTOLOGY] |
| - Pembrolizumab + - Pembrolizumab + |
| Carboplatin/Cisplatin + Carboplatin + |
| Pemetrexed (KEYNOTE-189) Paclitaxel / Nab-Paclitaxel (KEYNOTE-407) |
| - ABCP Quadruplet: - Nivolumab + Ipilimumab + |
| Atezolizumab + Bevacizumab+ 2c Platinum Doublet (CheckMate 9LA) |
| Carboplatin + Paclitaxel - Cemiplimab + Platinum Doublet |
| (IMpower150) |
+-----------------------------------------------------------------------------+
Landmark Frontline Chemoimmunotherapy Trials
- KEYNOTE-189 (Non-Squamous NSCLC): Double-blind Phase 3 trial comparing pembrolizumab (200 mg Q3W) + pemetrexed (500 mg/m2) + carboplatin (AUC 5) / cisplatin (75 mg/m2) x 4 cycles followed by maintenance pembrolizumab + pemetrexed versus chemotherapy alone. Pembrolizumab combination demonstrated a striking doubling in median overall survival (22.0 vs. 10.7 months; HR 0.56, p < 0.001) and significant PFS improvement across all PD-L1 strata (<1%, 1–49%, >=50%).
- KEYNOTE-407 (Squamous NSCLC): Phase 3 trial in metastatic squamous NSCLC evaluating pembrolizumab (200 mg Q3W) + carboplatin (AUC 6) + paclitaxel (200 mg/m2) or nab-paclitaxel (100 mg/m2 weekly) x 4 cycles followed by maintenance pembrolizumab. Demonstrates superior median OS (17.1 vs. 11.6 months; HR 0.71) and PFS.
- IMpower150 (ABCP Quadruplet in Non-Squamous): Evaluated atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) vs. BCP. Demonstrates survival advantage (mOS 19.5 vs 14.7 mo; HR 0.78), showing unique activity in patients with baseline liver metastases and sensitizing EGFR mutations progressing after TKIs.
- CheckMate 9LA (Dual Checkpoint + 2 Chemotherapy Cycles): Nivolumab (360 mg Q3W) + ipilimumab (1 mg/kg Q6W) + 2 cycles of histology-directed platinum doublet chemotherapy demonstrated superior OS over 4 cycles of chemotherapy alone (mOS 15.6 vs 10.9 months; HR 0.72).
Comprehensive Pemetrexed Supportive Care Protocol
+-----------------------------------------------------------------------------+
| CLINICAL PHARMACIST PEMETREXED PREMEDICATION PROTOCOL |
| |
| 1. FOLIC ACID SUPPLEMENTATION (Mandatory to prevent fatal myelosuppression)|
| - Dose: 400 mcg to 1000 mcg PO ONCE DAILY |
| - Timing: Must begin at least 7 DAYS PRIOR to Cycle 1 Day 1 |
| - Duration: Continue daily throughout treatment and for 21 DAYS after |
| the final pemetrexed dose. |
| |
| 2. VITAMIN B12 SUPPLEMENTATION (Protects against mucosal / hematologic tox)|
| - Dose: 1000 mcg (1 mg) INTRAMUSCULAR INJECTION |
| - Timing: First injection administered within 7 DAYS PRIOR to Cycle 1 |
| - Maintenance: Repeat once EVERY 3 CYCLES (approx. every 9-12 weeks) |
| |
| 3. DEXAMETHASONE CUTANEOUS PROPHYLAXIS (Prevents severe erythematous rash) |
| - Dose: 4 mg PO TWICE DAILY (BID) for 3 consecutive days: |
| * Day -1 (the day before pemetrexed) |
| * Day 0 (the day of pemetrexed administration) |
| * Day +1 (the day following pemetrexed) |
| |
| 4. RENAL FUNCTION CUTOFF & NSAID AVOIDANCE: |
| - Absolute Cutoff: Pemetrexed is CONTRAINDICATED if CrCl < 45 mL/min |
| - NSAID Interactions: If CrCl is 45-79 mL/min, hold short-acting NSAIDs|
| (ibuprofen) for 2 days before, day of, and 2 days after pemetrexed; |
| hold long-acting NSAIDs (naproxen, meloxicam) for 5 days before. |
+-----------------------------------------------------------------------------+
Bevacizumab Safety Precautions & Absolute Contraindications
- Histology Restriction: Bevacizumab is strictly restricted to non-squamous histology. In squamous NSCLC, VEGF inhibition causes central cavitary tumor necrosis, resulting in life-threatening or fatal pulmonary hemorrhage/hemoptysis.
- Absolute Contraindications: Active hemoptysis (>=2.5 mL of red blood), central cavitary tumors abutting major mediastinal vessels, uncontrolled severe hypertension, active gastrointestinal perforation/fistulae, and major surgery within 28 days (hold bevacizumab >=4–6 weeks before and after elective surgeries due to wound dehiscence).
2. Master Oncogenic Driver Target Profiling & Precision Therapeutics
+-----------------------------------------------------------------------------+
| ACTIONABLE ONCOGENIC DRIVER LANDSCAPE IN NSCLC |
| |
| [EGFR (15-20%)] ---> Ex19del / L858R: Osimertinib (FLAURA/FLAURA2) |
| ---> Exon 20 Ins: Amivantamab + Chemo (PAPILLON) |
| |
| [ALK (4-5%)] ---> Alectinib, Brigatinib, Lorlatinib (CROWN) |
| |
| [ROS1 (1-2%)] ---> Entrectinib, Repotrectinib, Crizotinib |
| |
| [BRAF (2-4%)] ---> V600E: Dabrafenib + Trametinib; Encorafenib + Bini |
| |
| [KRAS (25-30%)] ---> G12C (13%): Sotorasib, Adagrasib (2nd-Line) |
| |
| [MET (3-4%)] ---> Exon 14 Skipping: Capmatinib, Tepotinib |
| |
| [RET (1-2%)] ---> Selpercatinib, Pralsetinib |
| |
| [HER2 (2-3%)] ---> ERBB2 Activating Mutation: Trastuzumab deruxtecan |
| |
| [NTRK (0.2%)] ---> Fusions (NTRK1-3): Larotrectinib, Entrectinib |
+-----------------------------------------------------------------------------+
Comprehensive Master Matrix of Targeted Kinase Inhibitors & ADCs in NSCLC
| Biomarker Alteration | Preferred Frontline Agent(s) | Mechanism of Action | Standard Dosing & Schedule | Signature Toxicities & Monitoring Pearls |
|---|---|---|---|---|
| EGFR Classic (Ex19del, L858R) | Osimertinib | 3rd-generation irreversible mutant-selective TKI (Cys797 covalent binding) | 80 mg PO daily (with or without food) | QTc prolongation, LVEF reduction (cardiomyopathy), ILD/pneumonitis (2–4%), cytopenias, stomatitis. Spares wild-type EGFR (minimal skin toxicity). |
| EGFR Exon 20 Insertions | Amivantamab + Chemo | Fully human bispecific EGFR-MET antibody directed to extracellular domains | Amivantamab IV weekly x 4 weeks, then Q2W + Carboplatin/Pemetrexed | High rate of infusion-related reactions (IRRs in 65% on Day 1; mandatory split dosing D1/D2 and premedication with antihistamine, antipyretic, dexamethasone), rash, paronychia. |
| ALK Rearrangements | Alectinib (or Lorlatinib, Brigatinib) | Potent, brain-penetrant next-generation ALK/RET TKI | 600 mg PO BID with food | Elevated CPK/myalgia (monitor CPK Q2W for month 1), bradycardia, photosensitivity, elevated bilirubin. |
| ALK (High CNS / Resistance) | Lorlatinib | 3rd-generation compact macrocyclic ALK/ROS1 TKI (active vs. G1202R) | 100 mg PO daily | Severe hypercholesterolemia (80%) and hypertriglyceridemia (60%) -> start statin (rosuvastatin). Central neurocognitive/mood toxicities (hallucinations, cognitive slowing). |
| ROS1 Fusions | Entrectinib (or Repotrectinib, Crizotinib) | CNS-active ROS1 and TRK A/B/C tyrosine kinase inhibitor | 600 mg PO daily with or without food | Weight gain, dizziness/ataxia, paresthesias, hyperuricemia, cognitive changes, QTc prolongation, bone fracture risk. |
| BRAF V600E | Dabrafenib + Trametinib | BRAF monomer inhibitor + MEK1/2 allosteric inhibitor | Dabrafenib 150 mg PO BID + Trametinib 2 mg PO daily (empty stomach) | Pyrexia syndrome (55%): hold dabrafenib at >=38.5°C; resume upon resolution. Trametinib requires refrigeration (2–8°C). Serous retinopathy (RPED), LVEF decline. |
| KRAS G12C | Sotorasib (or Adagrasib) | Small-molecule covalent inhibitor binding the switch II pocket of GDP-bound KRAS(G12C) | Sotorasib 960 mg PO daily OR Adagrasib 600 mg PO BID | Sotorasib: Hepatotoxicity (AST/ALT elevation in 15–20%), diarrhea. Adagrasib: QTc prolongation, GI toxicity, potent CYP3A4 inhibitor/substrate. Used >=2nd line. |
| MET Exon 14 Skipping | Capmatinib (or Tepotinib) | Highly selective ATP-competitive type Ib MET kinase inhibitor | Capmatinib 400 mg PO BID OR Tepotinib 450 mg PO daily | Peripheral edema (50–60%): manage with elevation and compression (loop diuretics ineffective). Asymptomatic serum creatinine elevation via renal transporter (MATE1/OCT2) inhibition. |
| RET Fusions | Selpercatinib (or Pralsetinib) | Highly selective, CNS-active small-molecule RET kinase inhibitor | Selpercatinib 160 mg PO BID (or weight-tiered) | Secondary hypertension, transaminitis, QTc prolongation, dry mouth, hemorrhagic events, hypersensitivity reactions (fever, rash). |
| HER2 (ERBB2) Mutations | Trastuzumab deruxtecan (T-DXd) | HER2-directed antibody-drug conjugate with topoisomerase I inhibitor exatecan payload | 5.4 mg/kg IV Q3W | Boxed Warning for Interstitial Lung Disease (ILD/pneumonitis) in 12–15%; immediately hold for Grade 1 and permanently discontinue for Grade >=2. LVEF decrease, alopecia, severe nausea/emesis (moderate emetic risk). |
| NTRK 1/2/3 Fusions | Larotrectinib (or Entrectinib) | Highly selective pan-TRK kinase inhibitor (TRKA, TRKB, TRKC) | Larotrectinib 100 mg PO BID (capsule or oral solution) | Neurocognitive changes, dizziness, ataxia, rapid weight gain/hyperphagia, rebound withdrawal pain following sudden treatment cessation. |
3. Mechanisms of Acquired Resistance and Post-Progression Strategies
+-----------------------------------------------------------------------------+
| OSIMERTINIB RESISTANCE MECHANISMS & SECOND-LINE |
| |
| [OSIMERTINIB RESISTANCE EMERGENCE] |
| | |
| v |
| [REPEAT TISSUE / LIQUID BIOPSY NGS] |
| | |
| +---------------------------+---------------------------+ |
| | | | |
| v v v |
| [ON-TARGET TERTIARY] [OFF-TARGET BYPASS] [HISTOLOGIC SHIFT] |
| - EGFR C797S Mutation - MET Amplification (15-25%) - Transformation |
| * If in trans with T790M: * Osimertinib + to Small Cell |
| 1st-gen + Osimertinib Savolitinib / Amivantamab Lung Cancer |
| * If in cis with T790M: - HER2 Amplification (5%) (SCLC) (~5-10%) |
| Chemo / ADC * Trastuzumab deruxtecan * Treat with |
| - EGFR Exon 20 Mutations - BRAF V600E / RET / ALK Platinum + |
| * Amivantamab + Chemo * Matched targeted therapy Etoposide |
+-----------------------------------------------------------------------------+
Overcoming Resistance in ALK-Rearranged NSCLC
- Following first-line alectinib or brigatinib progression, repeat molecular profiling frequently reveals the ALK G1202R solvent-front mutation (~30–40% of secondary resistance). The bulky positively charged arginine side chain sterically clashes with 1st/2nd-generation ALK inhibitors.
- Lorlatinib is uniquely structurally configured as a compact, rigid macrocycle that fits into the kinase binding cleft despite the bulky G1202R mutation, producing objective response rates >40–50% and median PFS >6–9 months in alectinib-refractory disease.
4. Second-Line Driver-Negative Chemotherapy & Anti-Angiogenic Regimens
When driver-negative patients experience disease progression on frontline chemoimmunotherapy, standard second-line options include:
- Docetaxel + Ramucirumab (REVEL Trial): Docetaxel (75 mg/m2 IV Day 1) plus the VEGFR2 monoclonal antibody ramucirumab (10 mg/kg IV Day 1) every 21 days demonstrated a statistically significant OS improvement over docetaxel alone (median OS 10.5 vs. 9.1 months; HR 0.86, p = 0.023). Toxicities: neutropenia, febrile neutropenia (G-CSF primary prophylaxis recommended), hypertension, bleeding, stomatitis.
- Single-Agent Docetaxel: 75 mg/m2 IV Q21D with dexamethasone premedication.
- Pemetrexed Monotherapy: 500 mg/m2 IV Q21D (if non-squamous and not previously administered during frontline therapy).
Test Your Knowledge
A 67-year-old male is diagnosed with Stage IV metastatic lung adenocarcinoma. Molecular NGS testing confirms absence of EGFR, ALK, ROS1, BRAF, RET, MET, and KRAS driver alterations. PD-L1 IHC testing reveals a Tumor Proportion Score (TPS) of 0%. His baseline serum creatinine is 0.9 mg/dL (calculated CrCl 78 mL/min). The medical oncologist prescribes first-line therapy with carboplatin (AUC 5), pemetrexed (500 mg/m2), and pembrolizumab (200 mg) every 21 days (KEYNOTE-189 protocol). Which of the following supportive care regimens is mandatory to prevent severe, potentially life-threatening hematologic toxicity from pemetrexed?
A
B
C
D
Test Your Knowledge
A 54-year-old female with newly diagnosed metastatic lung adenocarcinoma presents with symptomatic bilateral pulmonary metastases and multiple osteolytic spinal lesions. Comprehensive NGS testing reveals an ALK-EML4 gene rearrangement. Brain MRI demonstrates three asymptomatic intracranial metastases (largest measuring 6 mm). Which of the following represents the most appropriate, guideline-recommended frontline systemic therapy?
A
B
C
D
Test Your Knowledge
A 62-year-old patient with metastatic ALK-rearranged NSCLC experiences systemic and intracranial disease progression after 28 months of initial disease control on first-line alectinib. Repeat molecular profiling from a newly progressing liver metastasis identifies the emergence of the secondary ALK G1202R solvent-front resistance mutation. Which of the following small-molecule inhibitors is specifically engineered to overcome this resistance mutation, and what signature toxicities require proactive clinical monitoring?
A
B
C
D
Test Your Knowledge
A 58-year-old non-smoking female with metastatic lung adenocarcinoma undergoes NGS profiling which reveals an activating HER2 (ERBB2) exon 20 insertion mutation. She experiences disease progression after 4 cycles of carboplatin and pemetrexed. Which of the following targeted agents is FDA-approved for this specific genomic alteration, and what is its most critical boxed warning?
A
B
C
D